Found 5 clinical trials
Bromocriptine in the Treatment of Peripartum Cardiomyopathy (BRO-HF)
anti-angiogenic effects that may promote PPCM. Bromocriptine, a central dopamine agonist known to decrease prolactin levels, might thwart its deleterious effects in women suffering from PPCM. Following
- 37 views
- 25 Feb, 2022
- 1 location
Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss
This research study investigates the use of a drug, cabergoline, given immediately after second-trimester abortion or perinatal loss to decrease breast engorgement. Cabergoline is a medication approved for the symptomatic treatment of pituitary adenomas that result in a hyperprolactinemic state (a brain tumor that results in milk leakage). The benefit …
- 1 views
- 01 Mar, 2021
- 1 location
Bromocriptine for Patients With Schizophrenia and Impaired Glucose Tolerance
This is a multicenter open-label, pilot study to evaluate the safety and tolerability of bromocriptine, a dopamine D2/D3 receptor and serotonin 5-HT2C receptor agonist, as an adjunct to
- 0 views
- 06 Feb, 2022
- 1 location
Dopamine Action on Metabolism in Relation to Genotype
, thus influencing the risk of overweight. In fact, preliminary results indicate that enhancing dopamine signaling with the dopamine agonist bromocriptine, depending on the FTO genotype, either induces
- 243 views
- 03 Mar, 2022
- 3 locations
Psychobiological Mechanisms Underlying Chronic Pain
Pain is a powerful motivator of behavior and it is more than the perception of nociceptive input. It is a complex experience that comprises different components: sensory discriminative, emotional-motivational and cognitive components. In chronic pain, a negative hedonic shift has been proposed that is characterized by disproportionally increased emotional-motivational compared …
- 0 views
- 12 Mar, 2022
- 1 location